AKI or acute kidney failure is a common medical condition reported among hospitalized patients, especially those with multiple comorbid conditions. AKI can occur due to various reasons including decreased renal perfusion, and obstruction of the urinary collecting system. Dehydration, abdominal pain, rise in blood pressure, mild back pain, and vomiting are some of the symptoms associated with the disease.
AKI is diagnosed through various tests which include measurement of rise in serum creatinine, urinary output and imaging techniques including renal ultrasonography. Consumption of medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), calcineurin inhibitors, and sulfonamide antibiotics, can result in AKI. Management of AKI requires in-depth understanding of fluid and electrolyte homeostasis, as well as appropriate use of renal replacement therapy (RRT).
According to the research findings, majority of pipeline drug candidates are being developed for intravenous route administration. The advantage with this administration includes entire administered dose reaches the systemic circulation immediately, which increases the bioavailability of drug. Administration of therapeutics for AKI through intravenous route has shown promising results in clinical studies.
In November 2018, Angion Biomedica Corp. and Sinovant Sciences HK Limited entered into a collaboration and license agreement for the development of ANG-3777 for the treatment of patients with delayed graft function (DGF) following kidney transplantation and AKI following open-heart surgery requiring cardiopulmonary bypass.
Similarly, in May 2016, A1M Pharma AB collaborated with CSL Behring LLC to investigate the potential of combination therapy of Alpha 1 Microglobulin (A1M) and plasma protein in patients suffering from pre-eclampsia and AKI. The endogenous protein A1M is expected to showcase several protective mechanisms in tissues.
Sentien Biotechnologies Inc., AM-Pharma B.V., and Quark Pharmaceuticals Inc., are some other major companies involved in the development of drug candidates for the treatment of AKI.
The Acute Kidney Injury Therapeutics Market Research Report Forecast is a valuable source of insightful data for business strategists.
It provides the industry overview with recent trends, size, share, growth analysis, historical, futuristic data, revenue, demand and strategic development.The entire Acute Kidney Injury Therapeuticsmarket has been sub-categorized into injury type, therapy and Distribution channel.
The report provides an analysis of these subsets with respect to the geographical segmentation.
This research study will keep marketer informed and helps to identify the target demographics for a product or service.Request a FREE Sample Copy of Global Acute Kidney Injury Therapeutics Market Report with Full TOC At: https://www.valuemarketresearch.com/contact/acute-kidney-injury-therapeutics-market/download-sampleBy Injury TypePre-renalIntrinsic renalPost-renalBy TherapyIntermittent hemodialysisContinuous renal replacement therapySustained low-efficiency dialysisBy Distribution ChannelHospital PharmaciesOnline PharmaciesOthersBrowse Full Global Acute Kidney Injury Therapeutics Market Research Report With TOC At: https://www.valuemarketresearch.com/report/acute-kidney-injury-therapeutics-marketThe research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the Acute Kidney Injury Therapeutics market include AngionBiomedica Corp., AM-Pharma, Quark Pharmaceuticals, Inc., Baxter International, Inc., Fresenius Medical Care AG & Co.
KGaA., B. Braun Melsungen AG, Asahi Kasei Medical Co., Ltd., and LG Chem.,and Others.
One of the prominent areas of Malignant Mesothelioma research today is around the development of an effective, tolerable, second-line treatment for recurrent cases.
This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Malignant Mesothelioma development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages: Clinical• Non-clinical • Inactive: Discontinued and/or Dormant Descriptive coverage of pipeline development activities for Malignant MesotheliomaPipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies, and patent details.
Pipeline Therapeutics assessment of products for Malignant MesotheliomaThe report assesses the active Malignant Mesothelioma pipeline products by developmental stage, product type, molecule type, and administration route.
Methodology Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis ’s team of industry experts.
